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Summary 
 
Adolescence is characterised by a dramatic increase in the incidence of tuberculosis, a fact 
that has been appreciated since the early 20th century. The majority of the world’s 
adolescents live in low and middle-income countries where tuberculosis remains common, 
and where they comprise one quarter of the population. Despite this, adolescents have not 
yet been addressed as a distinct population in tuberculosis policy or within tuberculosis 
treatment services, and emerging evidence suggests that current models of care do not 
meet their needs. 
 
This article reviews current knowledge about tuberculosis in adolescence with a focus on the 
management of infection and disease, including HIV co-infection and rifampicin-resistant 
tuberculosis. Recent progress in vaccine development is outlined and important directions 
for future research are highlighted. 
 
 
 
 
 
Search strategy and selection criteria  
 
This was a narrative review of the literature on adolescent tuberculosis, informed by expert 
opinion and clinical experience. We reviewed the English- and Spanish-language literature 
for studies on adolescent tuberculosis to identify case series documenting clinical 
presentation and treatment outcomes. We searched PubMed with the following string on 19 
August 2019: (‘tuberculosis’[Title]) AND (‘adolescent’[TIAB]). The search returned 210 
results, of which 11 were eligible for inclusion (Table 1), and we identified three additional 
studies from reference lists, for a total of 14 studies. Studies reporting solely on prevalence 
or where data from adolescents was aggregated with those of younger children or adults 
were excluded. Data were extracted regarding major site(s) of disease, percent of 
adolescents with microbiologic confirmation, adverse drug reactions, and final treatment 
outcomes. 
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Introduction 
 
Following the “golden years” of mid-childhood where tuberculosis cases drop significantly 
compared to early childhood, adolescence represents a period of increased susceptibility to 
tuberculosis, when both the prevalence of Mycobacterium tuberculosis (M.tb) infection and 
the incidence of tuberculosis disease rise considerably.1-4 The reasons for this are not 
completely understood, although it is thought that sex hormones, changing social contact 
patterns and immunological changes may each have a role.1 An estimated 1.8 million 
adolescents and young adults around the world develop tuberculosis disease each year, a 
burden which has been elucidated only recently due to a historical focus within tuberculosis 
surveillance on “children” (aged 0-14 years) and “adults” (aged ≥15 years), neglecting 
adolescents entirely.5 In high-burden settings, adolescents make up both a substantial 
proportion of the general population, and a substantial proportion of patients with 
tuberculosis.5 This creates a major need for high-quality tuberculosis services which are 
accessible and acceptable to adolescents, both to facilitate timely diagnosis and to support 
medication adherence and treatment completion. Despite the growing recognition of 
adolescence as a period of escalating risk and increasing burden of tuberculosis, to date, 
adolescents have not been addressed as a distinct population within tuberculosis control 
efforts. 
 
This review aims to summarise current knowledge about tuberculosis in adolescents from 
both a clinical and public health perspective, while also highlighting important knowledge 
gaps. In this review, adolescence is defined as 10-24 years of age, consistent with evidence 
that many developmental processes continue between age 18 and 24.6 We use ”young 
adolescents” to refer those aged 10-14 years, “older adolescents” to refer to those aged 15-
19, and “young adults” to refer to those aged 20-24. ‘M.tb infection’, also known as ‘latent 
tuberculosis infection’, refers to an asymptomatic carrier state prior to development of 
disease, whereas ‘tuberculosis’ refers to the presence of radiographic and clinical signs and 
symptoms attributable to tuberculosis disease, although these may be better understood as 
two points on a spectrum rather than two entirely distinct states.7 Figure 1 shows the 
estimated incidence of tuberculosis disease (panels A and B) and prevalence of M.tb 
infection (panels C and D) in children and adolescents around the world, from previous 
studies.5,8 Per capita figures are provided in the supplementary materials (Figure S1). 
Supplementary figure 2 shows the estimated number of people living with M.tb infection 
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across the entire age range; unfortunately the same estimation process is not currently 
possible for tuberculosis disease.  
 
 
Figure 1: Estimated numbers of people living with M.tb infection (panels A and B)8 and 
developing new or relapse tuberculosis disease (panels C and D)5. 
 
Clinical Management  
Tuberculosis 
 
Adolescents may present to tuberculosis services in one of three ways (Figure 2). First, they 
may be identified following exposure to M.tb as part of a contact tracing investigation. 
Second, they may present with symptoms or signs that could be consistent with a diagnosis 
of tuberculosis. Third, they may be referred following results from an investigation that then 
requires evaluation for tuberculosis disease. Commonly this includes imaging results in 
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which tuberculosis is in the list of differential diagnoses, or positive immune-based tests 
such as interferon gamma release assays (IGRAs) or the tuberculin skin test (TST).  
 
 
Figure 2: A suggested algorithm for the evaluation of adolescents who are referred for 
possible tuberculosis. 
 
 
In each of these three scenarios, the first step for the healthcare worker is to evaluate the 
adolescent for tuberculosis using a combination of history and examination, together with 
radiological and microbiological tests (smear microscopy, mycobacterial culture, and/or 
polymerase chain reaction (PCR) testing, e.g. MTB/Rif). Most adolescents have intrathoracic 
tuberculosis, defined as either parenchymal lung disease (infiltrates, cavities, miliary 
disease), pleural effusions, or intra-thoracic (hilar, mediastinal) lymphadenopathy.9 Common 
symptoms include cough, fever and weight loss. Findings on chest radiographs reflect the 
changes in pathogenesis that occur with age: adolescents more commonly present with 
cavitation and pleural effusions and less commonly with intra-thoracic lymphadenopathy or 
miliary disease, as seen in younger children.10-13 Parenchymal changes are more likely to be 
apical, as in adults. Table 1 shows the major sites of disease and prevalence of confirmed 
disease in case series of adolescents with tuberculosis identified during this review.10-12,14-24 
 
While peripheral (most commonly cervical) lymphadenopathy is often reported as the next 
most common site of disease in adults, it has infrequently been reported in adolescents. Up 
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to 4% of adolescents in two series had tuberculous meningitis,11,16 although this may be 
explained by selection bias resulting from those with more severe forms of tuberculosis 
being more likely to be identified and correctly diagnosed. The prevalence of symptoms, 
pulmonary disease, and microbiologic confirmation are likely overestimated in most case 
series for the same reasons. When resources are available, radiological evaluation for extra-
thoracic tuberculosis might include ultrasonography, computerised tomography or magnetic 
resonance imaging to identify enlarged lymph nodes, typical intracranial features or 
involvement of bone or soft tissue. 
  
Unlike for young children, in whom gastric aspirates or induced sputum are required to 
obtain respiratory samples, adolescents are usually able to expectorate sputum. Using saline 
to induce coughing has been associated with increased culture yields compared to 
spontaneously produced samples in children and young adolescents.26 Adolescents with 
pulmonary tuberculosis commonly have “bacteriologically confirmed” disease (i.e. smear, 
culture or PCR positive),9-11,16,19,26 although paucibacillary disease remains common and 
negative test results do not rule out tuberculosis. Yields from multiple samples (usually two) 
collected on the same day have been shown to be similar to samples collected on separate 
days in children, potentially making sample collection less burdensome and more feasible.27 
The new generation Xpert MTB/RIF Ultra has greater sensitivity than the previous test, Xpert 
MTB/RIF.28 Many adolescents with pulmonary disease are able to transmit M.tb, and due to 
the high number of social contacts made by adolescents (including outside the household, in 
schools and peer networks), contact investigation around adolescent patients should be a 
priority. 
 
In those with large pleural effusions, pleural taps or biopsies can be undertaken for 
microbiological and biochemical examination. An adenosine deaminase level greater than 40 
IU/L has high sensitivity to distinguish tuberculosis from other causes of effusion in children 
and young adolescents; however, yields from molecular tests and culture performed on 
pleural fluid vary widely.29 For adolescents with extra-thoracic disease, confirming the 
diagnosis can be challenging. Lymph node aspiration biopsy is safe, feasible and associated 
with good sensitivity and specificity in adolescents.30 Microbiologic confirmation of 
abdominal, renal, genitourinary, meningeal and musculoskeletal tuberculosis generally 
requires more invasive sampling, and yields from culture and molecular testing are lower 
than for thoracic disease. 
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The recommended drug therapy for tuberculosis in adolescents is the same as for younger 
children and adults, although it may be appropriate to dose on ideal or lean weight in obese 
adolescents.31 There are very sparse data on adverse event rates in adolescents (see Table 
1), however asymptomatic elevated liver transaminases are seen relatively commonly.12 
Likewise, few studies report any aspect of adherence to tuberculosis treatment in 
adolescents, including those with M.tb infection, for whom lack of symptoms makes 
adherence even more challenging.32 Several studies have investigated tuberculosis 
treatment outcomes among adolescents, and comparative studies show higher rates of loss 
to follow-up than children and adults in the same settings.15,19 However, premature 
disengagement from care lies at one extreme end of the adherence spectrum; partial 
adherence is more common than non-adherence in most other conditions. In one study 
from South Africa, 41% of 330 adolescent patients took fewer than 80% of the prescribed 
doses of their tuberculosis treatment.20  
 
At present, evidence for tuberculosis-specific adherence support interventions for 
adolescents is completely absent. However, the principles underpinning adherence–
promoting interventions for adolescents are well established for HIV, diabetes, and other 
chronic diseases, which equally apply to adolescents with tuberculosis. A critical issue is the 
‘adolescent-friendliness’ of services. A recent systematic review synthesised the evidence 
about young people’s priorities in healthcare, which identified the importance of respectful 
attitudes among technically competent staff and the delivery of clinically appropriate care in 
environments that are age-appropriate, clean and welcoming.33 Adolescents on tuberculosis 
treatment who are no longer contagious may benefit from peer support groups, which have 
been demonstrated to help adolescents with HIV to remain engaged with care.34 Computer-
based interventions and text messaging have also been shown to improve adherence and 
retention in care for adolescents with HIV, and offer tools to assist with therapeutic 
adherence.35 Educational interventions (including efforts to reduce stigma), behavioural 
interventions and peer support may also have a role, and involvement of supportive family 
members can be helpful. 
 
M.tb Infection 
Adolescents may be referred for assessment for M.tb infection through contact tracing, or 
due to a positive result on a TST or IGRA test. When deciding whether to treat M.tb 
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infection, the risk of future progression to disease needs to be evaluated together with the 
individual and public health benefits of prevention, and weighed against the risk and burden 
of treatment. While treatment of M.tb infection is relatively safe, adverse events do occur.36 
Risk factors for progression include recent exposure, any degree of immunosuppression,37 
especially HIV;38 low body mass index;39 and a positive IGRA or TST.40 The World Health 
Organization (WHO) now recommends that testing and treatment for M.tb infection can be 
offered to all close contacts of people with bacteriologically confirmed pulmonary 
tuberculosis, regardless of their age or HIV status.41 While having a positive TST or IGRA is 
associated with increased risk of future disease progression compared to a negative test, the 
vast majority of those with positive tests will never develop disease (especially in high 
burden settings where the background prevalence of infection is higher), necessitating 
treatment of many adolescents with infection to prevent each case of disease. Conversely, 
false negative TSTs and IGRAs can occur, 40 and a negative results does not necessarily 
indicate that preventive treatment is unwarranted.  
 
Isoniazid, taken daily for six or nine months, is associated with a reduction in risk of future 
tuberculosis disease in all age groups and has been the mainstay of treatment for M.tb 
infection for fifty years.42 Newer alternatives to the six or nine month isoniazid regimen 
include three months of daily therapy with both isoniazid and rifampicin,43 three months of 
weekly isoniazid and rifapentine,44 four months of daily rifampicin45 and one month of daily 
isoniazid and rifapentine.46 Compared to nine-month regimens, shorter regimens are 
associated with improved adherence - a particular issue in adolescents47 - and at least 
equivalent efficacy, with no increase in adverse events.36,45  
 
Tuberculosis prevention has been historically neglected in high tuberculosis burden settings 
due to resource constraints.47 The Sustainable Development Goals place new emphasis on 
prevention, as demonstrated in both the End TB Strategy48 and in the WHO/UNICEF 
Roadmap Towards Ending Tuberculosis in Children and Adolescents.49 While standard 
practice in high-income countries, the updated WHO guidelines on treatment for M.tb 
infection are a substantial expansion of current policies in low- and middle-income 
countries, with direct relevance to adolescents. High quality evidence on how to address 
health system and other barriers to facilitate wider administration of treatment for M.tb 
infection in children, adolescents and adults is needed in diverse settings.49 This issue is yet 
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more complex in the case of preventive therapy for children and adolescents exposed to 
multidrug-resistant tuberculosis, which is the subject of current clinical trials.  
 
Rifampicin Resistant Tuberculosis 
 
Rifampicin-resistant (RR) tuberculosis includes multidrug-resistant (MDR; resistance to at 
least rifampicin and isoniazid) and extensively drug-resistant tuberculosis (XDR; MDR with 
additional resistance to at least one fluoroquinolone and at least one second-line injectable 
agent). A confirmed diagnosis of RR tuberculosis relies on microbiological confirmation from 
clinical samples or cultured isolates, using genotypic or phenotypic drug susceptibility tests 
(DSTs), which can be challenging in children and young adolescents.51 In the absence of rapid 
molecular DSTs, or in the case of patients with culture-negative tuberculosis, a clinical 
diagnosis of RR tuberculosis can be made in symptomatic adolescents based on exposure to 
an index patient with bacteriologically confirmed RR tuberculosis, or lack of clinical 
improvement (i.e. symptom resolution and weight gain) after at least two months of first-
line therapy with good adherence (provided the risk of misdiagnosis of another chronic lung 
condition is low).52  
 
Composition and duration of second-line treatment regimens for adolescents with adult-
type disease and bacteriological confirmation of RR tuberculosis is generally the same as for 
adults. The 2019 WHO recommendations for use of novel drugs in RR tuberculosis treatment 
also apply to adolescents, as available pharmacokinetic data indicate that delamanid and 
bedaquiline may be given to children as young as three and six years of age, respectively.53 
For younger adolescents with paucibacillary disease that is clinically diagnosed without 
bacteriological confirmation of drug susceptibility, regimen composition should consider the 
adolescent’s exposure history and the drug susceptibility results of the likely index patient, if 
known. Young adolescents with culture-negative, non-severe RR tuberculosis disease have 
been shown to have excellent outcomes with total treatment duration of 12 months.54  
 
Few reports have characterised the frequency and impact of adverse effects of RR 
tuberculosis treatment in adolescents. A small case series from India reported that 5 of 8 
HIV-positive adolescents treated for MDR tuberculosis experienced a moderate or severe 
adverse event during their TB treatment (see Table 1), including psychosis, convulsions, 
hypokalemia, and gastrointestinal intolerance.22 A review of eight case reports of 18 children 
and young adolescents receiving linezolid-based regimens suggests that haematologic 
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toxicity and neuropathies occur less commonly than in adults.55 QT prolongation is a concern 
among patients receiving bedaquiline, delamanid, clofazimine, and/or fluoroquinolones, but 
data are limited in adolescents.56 Among 16 children aged 8-17 years receiving delamanid, 
one experienced clinically significant adverse effects, including QT prolongation.57 Among 27 
adolescents receiving bedaquiline-containing regimens, five experienced clinically significant 
QT prolongation; these events were managed without withdrawal of bedaquiline.58 Skin 
discolouration is a common adverse effect of clofazimine.59 Skin hyperpigmentation has 
been associated with poorer perceived quality of life in younger adults (aged <35 years),60 so 
this effect is likely to be distressing and stigmatising for adolescents and may lead to 
decreased adherence and treatment discontinuation.  
 
Delayed diagnosis, treatment refusal and loss to follow-up were common and serious issues 
in two RR tuberculosis case series from South Africa and India (see Table 1).22,23  Several 
adolescents in both studies were diagnosed so late that they died either before or shortly 
after initiation of treatment, and several more died after being lost to follow-up during 
treatment. These sobering experiences highlight the intense vulnerability of many 
adolescents with RR tuberculosis and the challenges of successfully engaging them in care.  
 
HIV-associated Tuberculosis 
 
Globally, HIV is the second leading cause of death among 10-19 year old adolescents, and 
HIV-related deaths have tripled in this age-group since 2000.61 This increase occurred 
predominantly in the African Region, where 90% of the world’s children and adolescents 
with HIV live, and during a period when HIV-related deaths were decreasing in all other 
population groups. HIV mortality in adolescents has largely been driven by delayed diagnosis 
and treatment of perinatally-acquired infection, as HIV infection acquired during 
adolescence will usually progress to severe disease only after many years.62 Due to 
suboptimal coverage of HIV diagnosis in early infancy, many perinatally-infected children 
have been diagnosed only in older childhood and adolescence, when they were already 
severely immunosuppressed.63,64 The scale-up of antiretroviral therapy (ART) since 2003 has 
had a profound impact on tuberculosis incidence, morbidity and mortality, but these each 
remain higher in adolescents with HIV compared to the general adolescent population.65 
Adherence to HIV treatment often drops in adolescence, and HIV viral suppression rates are 
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lower in adolescents than in other age-groups.66,67 This increases the risk of 
immunosuppression and with it the risk of developing tuberculosis. 
 
Adolescents living with HIV should be assessed for initiation of both ART and treatment for 
M.tb infection. The updated and consolidated WHO guidelines for programmatic 
management of M.tb infection recommend treatment of M.tb infection for adolescents 
living with HIV and an unknown or a positive TST result, provided they are assessed as being 
unlikely to have tuberculosis disease.68 Treatment for M.tb infection should be given 
irrespective of the degree of immunosuppression, ART, history of previous tuberculosis 
treatment and pregnancy. Clinicians administering both ART and treatment for M.tb 
infection should be aware of potential drug interactions and follow appropriate guidelines to 
avoid these. This is particularly important given the increasing use of rifamycins for M.tb 
infection treatment, which can adversely affect ART metabolism. 
 
Tuberculosis disease remains the main cause of mortality among adolescents living with 
HIV.69 The presence of HIV co-infection compounds the well-recognised challenges of 
reaching a definitive diagnosis in children and adolescents with suspected tuberculosis.70 
Extrapulmonary and disseminated disease patterns are more common, tuberculosis is 
typically paucibacillary, and chest radiographic appearances are not typical.71 Notably, in 
recent years, studies have reported a high prevalence of chronic respiratory disease in 
adolescents with long-standing HIV, even among those taking ART.72 Chronic lung disease in 
the context of HIV infection may be a sequela of previous respiratory tract infections 
including tuberculosis, or HIV itself. In low-income settings where pulmonary diagnostics 
such as high resolution computed tomography and lung function testing are not readily 
available, these symptoms often result in misdiagnosis of tuberculosis and unnecessary 
empirical tuberculosis treatment, particularly in children and adolescents, who tend to have 
chronic, non-specific abnormalities on chest radiography.73,74  
 
If not already on ART, any adolescent with HIV diagnosed with tuberculosis should be 
started on ART as soon as is practically possible, following the start of tuberculosis 
treatment.75 It is common to wait a short period of time to allow the individual to become 
accustomed to tuberculosis treatment before starting ART, but this should not usually be 
more than a couple of weeks. Treatment of tuberculosis in HIV is further complicated by the 
risk of immune reconstitution syndrome, and pharmacokinetic interactions and overlapping 
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toxicities between ART and anti-tuberculous drugs, particularly when second-line ART or RR 
tuberculosis regimens are required.76 For example, concurrent administration of isoniazid 
preventive therapy with nevirapine resulted in high rates of hepatotoxicity among children 
and adolescents living with HIV.77 
 
Tuberculosis and HIV both represent major threats to public health. Yet the historical 
neglect of adolescents as a key population within HIV control may be one reason why there 
has been little change in HIV mortality in this age group.78 Recent recognition of the 
importance of adolescents within HIV control efforts is a positive change. Research is 
urgently required to inform evidence-based management of tuberculosis and HIV in this age 
group, including development of appropriate diagnostic algorithms, optimal approaches to 
tuberculosis prevention, and best practices for adherence support.  
 
Specific Considerations for Adolescents during Tuberculosis Treatment 
 
The developmental period of adolescence can be challenging for paediatric and adult 
providers alike. In part this is due to adolescents’ desire for autonomy, and their prioritising 
short-term social benefits over potential long-term health gains.79 Several topics need to be 
broached with adolescents prior to initiating therapy (Figure 3), including adherence with 
appointments and medication, the effect of health-compromising behaviours (including 
substance use), interruption of education and employment, and the effects of social (and 
medical) isolation and stigma. The legal circumstances of the adolescent may need to be 
explored if they have an uncertain or precarious immigration status, or face other structural 
barriers to accessing healthcare. 
 
Medication adherence and loss to follow-up are serious concerns for health professionals 
managing adolescents with tuberculosis, especially in those with HIV co-infection and/or RR 
tuberculosis.22,23 Adherence support is of the utmost importance in this age group, 
particularly for adolescents with RR tuberculosis, who endure more adverse effects and 
longer duration of treatment than those treated for drug-susceptible disease, or those with 
complex co-morbidities such as HIV, diabetes, or substance dependence. Children and 
adolescents with RR tuberculosis report social isolation, stigmatisation, depression, and poor 
self-esteem,80,81 highlighting the importance of psychosocial support during tuberculosis 
treatment. 
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Adolescents with pulmonary tuberculosis may require isolation until they cease to be 
contagious, which should be closely monitored during treatment. This public health reality 
can prevent adolescents attending school or work, leading to short and long-term economic 
ramifications. However, some adolescents may also be unnecessarily excluded from school 
due to unfounded concerns about infection risks, for example those with exclusively 
extrapulmonary disease. Unnecessary exclusion from school and other regular activities 
should be minimised, and adolescents who cannot attend school should receive appropriate 
educational support until they can return.  
 
Tuberculosis treatment must be delivered with full knowledge of other health issues, 
medications (including contraception) and behaviours such as harmful substance use that 
might increase side effects or limit the efficacy of treatment. While it is unlikely that a 
polysubstance-using adolescent will stop using all substances, adolescents need guidance on 
which substances are most problematic during tuberculosis treatment. Adolescents should 
be informed that alcohol use is particularly harmful, as it can increase problematic side 
effects including hepatotoxicity,82 and may increase the risk of adverse treatment 
outcomes.83 Providers also need to discuss which modalities of substance use would be 
more likely to transmit M.tb, such as sharing water pipes or “bongs” when using marijuana, 
and “shotgunning" (a practice of inhaling smoke and then exhaling it into another person's 
mouth), so that patients can adjust their usage habits to protect their peers.84 Substance 
dependence should be addressed through referral to appropriate evidence-based services, 
for example medication-assisted treatment for adolescents with opioid dependence. 
 
Providers should counsel adolescent girls on non-hormonal contraception options (e.g. 
intrauterine devices or condoms) which are not adversely affected by rifamycins, as 
hormonal contraception cannot be relied upon during tuberculosis treatment.85 Pregnancy 
testing should be performed prior to provision of therapy so that pregnant adolescents can 
be appropriately referred for prenatal care. Testing for other sexually-transmitted infections 
should be offered at the time adolescents are tested for HIV infection, as incidence rates are 
usually highest in this age group.86 To improve quality care for adolescents, provision of 
tuberculosis care must therefore include the opportunity for confidential consultations; 
adolescents are less likely to accurately report their sexual activity, substance use and 
mental health status when parents or caregivers are present.87 
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Sequelae post tuberculosis 
 
Adolescence is a critical time for physical, psychosocial, and cognitive development—all of 
which may be impacted by tuberculosis (Figure 3). Yet little is known about the long-term 
consequences of tuberculosis on health and wellbeing in this age group. For example, there 
are no studies of the extent and consequence of school absence in connection with 
tuberculosis treatment. A few published studies describe neurological sequelae after 
tuberculosis meningitis, which occur in 54-66% of successfully treated patients ≤18 years,88,89 
and irreversible hearing loss due to injectable agents in patients treated for RR 
tuberculosis.90  
 
 
Figure 3: Tuberculosis in the life course: general and adolescent-specific risk factors 
associated with Mycobacterium tuberculosis infection, progression to tuberculosis disease, 
and outcomes.  
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No studies have evaluated post-tuberculosis lung health in adolescents or children. In adults, 
pulmonary tuberculosis is a well-established risk factor for chronic airflow obstruction and 
bronchiectasis,91 however extrapolating data from adults to adolescents is suboptimal for 
several reasons. Unlike adult lungs, adolescent lungs are still growing in volume and 
developing gas exchange capability, which may make them especially vulnerable.92 
Understanding post-tuberculosis lung function has important clinical implications, but in 
most high-burden settings people who complete tuberculosis treatment receive minimal 
follow-up. It has been shown that former adult tuberculosis patients with residual lung 
abnormalities experience diminished quality of life,93 and such patients can benefit from 
supportive measures, such as pulmonary rehabilitation.94 
 
The long-term psychosocial impact of tuberculosis in adolescence is also undocumented. In 
addition to interrupting education and employment, tuberculosis disease and its treatment 
can disrupt relationships with family and peers. Adolescents are intensely sensitive to social 
exclusion, and the impact of stigma and discrimination during adolescence can be profound 
and long-lasting. For example, in South Asia, young women with tuberculosis report 
diminished marriage prospects.95 Qualitative and mixed methods research around the 
breadth of developmental issues that tuberculosis might affect – including schooling, work, 
relationships and mental health – would be of great value.   
 
Tuberculosis vaccines 
 
Bacillus Calmette–Guérin (BCG) is the only vaccine currently available to prevent 
tuberculosis. There is clear evidence of a strong protective effect (90%) of initial BCG 
vaccination against disseminated TB in infants, and moderate protection (60-75%) against 
pulmonary disease in children and young adolescents.96 Large-scale trials of BCG conducted 
by the British Medical Research Council in the 1960s involved 14-15 year old adolescents 
and found that the BCG vaccine was 87% protective against disease, and 74% protective 20 
years later.97 This effect was, however, only seen in those who had not yet been sensitised 
to M.tb or nontuberculous mycobacteria. Mycobacterial sensitisation, measured using the 
TST, was suspected to limit any additional protection provided by the BCG vaccine.  
 
As the search for a more protective vaccine continues, greater attention is being paid to 
adolescents both with and without evidence of exposure to M.tb. Population groups at 
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increased risk of M.tb infection and disease, such as adolescents, are ideal participants to 
include in clinical trials, as primary endpoints can be achieved with smaller sample sizes. In 
addition, modelling suggests that a vaccine targeted to adolescents would have the most 
rapid and cost-effective outcome on the global tuberculosis epidemic.98 
 
Several clinical trials of new vaccine candidates are enrolling adolescents. In the recently 
published Phase 2 HYVAC4 trial, 990 HIV-negative, BCG-vaccinated, IGRA-negative 
adolescents between the ages of 12 and 17 years living in a tuberculosis endemic setting 
were randomly assigned to receive the H4:IC31 vaccine, BCG revaccination, or placebo.99 
Results suggested that BCG revaccination provided 45% protection against sustained M.tb 
infection, while the effect of the H4:IC31 vaccine to prevent sustained infection did not 
reach statistical significance. Concomitant laboratory data showed that BCG revaccination 
was found to significantly boost BCG-specific CD4+ T-cell responses. Whilst disappointing for 
the HYVAC4 vaccine candidate, the findings suggest that BCG revaccination of QFT-negative 
adolescents may provide additional benefit, leading to renewed interest in BCG 
revaccination in adolescence.100 
 
Another recent Phase 2b controlled trial randomised 3,575 HIV-negative individuals aged 18-
50 years with evidence of M.tb infection in 11 centres in South Africa, Kenya, and Zambia to 
the M72/AS01E vaccine or placebo.101 The candidate vaccine showed significant efficacy in 
the prevention of tuberculosis disease, with an overall vaccine efficacy of 54%. In pre-
specified sub-analyses, vaccine efficacy varied considerably by age: vaccine efficacy was 
84.4% in 18-25 year old participants, compared to 10.2% in those older than 25. The 
importance of previous BCG vaccination and previous M.tb sensitisation on the efficacy of 
this vaccine candidate remains to be defined. However, if generalisable, the results suggest 
that the vaccine is likely to be effective when administered to adolescents. 
 
Conclusion 
 
Important questions remain regarding many biological, clinical and psychosocial aspects of 
tuberculosis in adolescence. Most tuberculosis literature divides the population into two age 
groups: “children” 0–14 years and “adults” aged ≥15 years. However adolescence is defined, 
adolescents have been ignored using this classification, resulting in a data void. There is an 
urgent need to better understand tuberculosis epidemiology, prevention, and management 
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among adolescents, including those with HIV or drug-resistant disease. However, much is 
already known about effective tuberculosis control and how to provide high-quality health 
services for adolescents with complex health conditions. The ambitious goals for 
tuberculosis control in the coming decades demand a comprehensive response. Success in 
the fight to end tuberculosis will hinge in large part on whether we can meet the needs of 
the current generation of adolescents for effective prevention, diagnosis, and management 
of this disease.    
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Supplementary Figures 
 
 
 
Supplementary figure 1: Estimated numbers of people living with M.tb infection (panels A 
and B)8 and developing new or relapse tuberculosis disease (panels C and D)5, per 100,000 
population.  
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Supplementary figure 2: The estimated number of people living with M.tb infection in each 
WHO region and globally, disaggregated by five-year age band.8 
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